RT Journal Article
SR Electronic
T1 A Molecular network approach reveals shared cellular and molecular signatures between chronic fatigue syndrome and other fatiguing illnesses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.29.21250755
DO 10.1101/2021.01.29.21250755
A1 Comella, Phillip H.
A1 Gonzalez-Kozlova, Edgar
A1 Kosoy, Roman
A1 Charney, Alexander W.
A1 Peradejordi, Irene Font
A1 Chandrasekar, Shreya
A1 Tyler, Scott R.
A1 Wang, Wenhui
A1 Losic, Bojan
A1 Zhu, Jun
A1 Hoffman, Gabriel E.
A1 Kim-Schulze, Seunghee
A1 Qi, Jingjing
A1 Patel, Manishkumar
A1 Kasarskis, Andrew
A1 Suarez-Farinas, Mayte
A1 Gümüş, Zeynep H.
A1 Argmann, Carmen
A1 Merad, Miriam
A1 Becker, Christian
A1 Beckmann, Noam D.
A1 Schadt, Eric E.
YR 2021
UL http://medrxiv.org/content/early/2021/02/02/2021.01.29.21250755.abstract
AB The molecular mechanisms of chronic fatigue syndrome (CFS, or Myalgic encephalomyelitis), a disease defined by extreme, long-term fatigue, remain largely uncharacterized, and presently no molecular diagnostic test and no specific treatments exist to diagnose and treat CFS patients. While CFS has historically had an estimated prevalence of 0.1-0.5% [1], concerns of a “long hauler” version of Coronavirus disease 2019 (COVID-19) that symptomatically overlaps CFS to a significant degree (Supplemental Table-1) and appears to occur in 10% of COVID-19 patients[2], has raised concerns of a larger spike in CFS [3]. Here, we established molecular signatures of CFS and a corresponding network-based disease context from RNA-sequencing data generated on whole blood and FACs sorted specific peripheral blood mononuclear cells (PBMCs) isolated from CFS cases and non-CFS controls. The immune cell type specific molecular signatures of CFS we identified, overlapped molecular signatures from other fatiguing illnesses, demonstrating a common molecular etiology. Further, after constructing a probabilistic causal model of the CFS gene expression data, we identified master regulator genes modulating network states associated with CFS, suggesting potential therapeutic targets for CFS.Competing Interest StatementThe external patient data used to build the Bayesian network were partially funded as part of research alliance between Janssen Biotech and The Icahn School of Medicine at Mount Sinai.Funding StatementZHG acknowledges funding from grant UL1 TR001863/TR/NCATS NIH HHS/United StatesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study-related activities were conducted under the approval and oversight of Mount Sinai Institutional Review Board (IRB).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in this manuscript will be included in this submission. An interactive website containing the signatures, co-expression modules, key drivers, and Bayesian network can be found here: https://irenefp.github.io/bcellm7.html